Skip to main content
Signal8
Launch Terminal

NEKTAR THERAPEUTICS (NKTR)

Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Nektar Therapeutics logo

Nektar Therapeutics

NASDAQ:NKTRHealthcare
-0.79%$38.87
AH$38.50-0.95%vs close
Mkt Cap$1.33B
Float33.25M
O/S34.14M
Vol
$ Vol
RVOL
Inst Own-
SI21.1%
Earnings
Dilution
Nektar Therapeutics logoNASDAQ:NKTR$38.87-0.79%
Phase Distribution
39 lead-sponsored trials·3 active·27 completed
Phase 113
Phase 1/25
Phase 211
Phase 2/32
Phase 38
(22 more as collaborator)
Status Overview
Recruiting2
Active, not recruiting1
Completed27
Stopped9

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Completed

    The BEACON Study (Breast Cancer Outcomes With NKTR-102)

    NKTR-102, Treatment of Physician's Choice (TPC)

    Locally Recurrent Breast Cancer, Metastatic Breast Cancer

    Enrollment
    852
    Start
    Dec 2011
    Primary Completion
    Apr 2016
    Completion
    Jun 2016
    NCT01492101
  • Phase 3
    Completed

    Efficacy and Safety Study of NKTR-181 in Opioid-Naive Subjects With Low Back Pain

    NKTR-181 BID tablets, Placebo to match NKTR-181 BID tablets

    Low Back Pain, Chronic Pain

    Enrollment
    1,189
    Start
    Mar 2015
    Primary Completion
    Dec 2016
    Completion
    Feb 2017
    NCT02362672
  • Phase 3
    Completed

    Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Cancer Pain

    NKTR-181 BID tablets

    Low Back Pain, Chronic Pain

    Enrollment
    638
    Start
    Apr 2015
    Primary Completion
    Dec 2017
    Completion
    Jan 2018
    NCT02367820
  • Phase 3
    Completed

    A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine

    NKTR-102, Eribulin

    Metastasis, Breast Cancer

    Enrollment
    178
    Start
    Nov 2016
    Primary Completion
    Jul 2020
    Completion
    Jul 2020
    NCT02915744
  • Phase 3
    Terminated

    A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)

    bempegaldesleukin, sunitinib

    Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma

    Enrollment
    623
    Start
    Dec 2018
    Primary Completion
    Jan 2022
    Completion
    Oct 2022
    NCT03729245
  • Phase 3
    Terminated

    Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence

    Bempegaldesleukin, Nivolumab

    Melanoma, Melanoma Stage III +2

    Enrollment
    765
    Start
    Jul 2020
    Primary Completion
    Sep 2022
    Completion
    Sep 2022
    NCT04410445
  • Phase 3
    Recruiting

    A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

    Rezpegaldesleukin, Placebo

    Moderate-to-Severe Atopic Dermatitis

    Enrollment
    510
    Start
    Jun 2026
    Primary Completion
    May 2028est.
    Completion
    Dec 2028est.
    NCT07690371
  • Phase 3
    Recruiting

    A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

    Rezpegaldesleukin, Placebo

    Moderate-to-Severe Atopic Dermatitis

    Enrollment
    510
    Start
    Aug 2026
    Primary Completion
    Jun 2028est.
    Completion
    Jan 2029est.
    NCT07711418
  • Phase 2/3
    Terminated

    BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)

    Bempegaldesleukin, Pembrolizumab

    Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer

    Enrollment
    1
    Start
    Mar 2022
    Primary Completion
    Apr 2022
    Completion
    Apr 2022
    NCT04969861
  • Phase 2/3
    Terminated

    NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma

    NKTR-255 at 1.5 µg/kg, NKTR-255 at 3.0 μg/kg

    Non-Hodgkin Lymphoma, Relapsed/Refractory Diffuse Large B-cell Lymphoma

    Enrollment
    15
    Start
    Feb 2023
    Primary Completion
    May 2024
    Completion
    Aug 2024
    NCT05664217
  • Phase 2
    Completed

    NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b)

    NKTR-102 100 mg/m2, NKTR-102 125 mg/m2

    Tumor, Colorectal Cancer

    Enrollment
    18
    Start
    Feb 2008
    Primary Completion
    May 2009
    Completion
    Dec 2011
    NCT00598975
  • Phase 2
    Completed

    Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer

    NKTR-102, NKTR-102

    Tumor, Breast Cancer

    Enrollment
    70
    Start
    Oct 2008
    Primary Completion
    Oct 2011
    Completion
    Jan 2012
    NCT00802945
  • Phase 2
    Completed

    Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer

    NKTR-102 q14d, NKTR-102 q21d

    Tumor, Ovarian Cancer

    Enrollment
    178
    Start
    Oct 2008
    Primary Completion
    Oct 2012
    Completion
    Jan 2013
    NCT00806156
  • Phase 2
    Completed

    NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer

    NKTR-102, irinotecan

    Colorectal Cancer

    Enrollment
    83
    Start
    Dec 2008
    Primary Completion
    Jul 2014
    Completion
    Dec 2014
    NCT00856375
  • Phase 2
    Completed

    An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies

    NKTR-102 145 mg/m2, NKTR-102 120 mg/m2

    Malignant Solid Tumor

    Enrollment
    27
    Start
    Oct 2011
    Primary Completion
    Aug 2017
    Completion
    Nov 2017
    NCT01457118
  • Phase 2
    Completed

    A Phase 2 Study To Assess The Efficacy, Tolerability, And Safety OF NKTR-181 In Subjects With Chronic OA Knee Pain

    NKTR-181, Placebo

    Osteoarthritis of the Knee

    Enrollment
    296
    Start
    Jun 2012
    Primary Completion
    Aug 2013
    Completion
    Sep 2013
    NCT01619839
  • Phase 2
    Completed

    A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer

    Bempegaldesleukin, Nivolumab

    Urinary Bladder Neoplasm, Neoplasm Metastasis

    Enrollment
    192
    Start
    Apr 2019
    Primary Completion
    Feb 2022
    Completion
    Jun 2022
    NCT03785925
  • Phase 2
    Completed

    A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)

    LY3471851, Placebo

    Systemic Lupus Erythematosus

    Enrollment
    291
    Start
    Aug 2020
    Primary Completion
    Jan 2023
    Completion
    Feb 2023
    NCT04433585
  • Phase 2
    Terminated

    A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)

    LY3471851, Placebo

    Colitis, Ulcerative

    Enrollment
    81
    Start
    Mar 2021
    Primary Completion
    Aug 2022
    Completion
    Aug 2022
    NCT04677179
  • Phase 2
    Active, not recruiting

    A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis

    Rezpegaldesleukin, Placebo

    Moderate to Severe Atopic Dermatitis

    Enrollment
    396
    Start
    Nov 2023
    Primary Completion
    May 2025
    Completion
    Dec 2026est.
    NCT06136741
  • Phase 2
    Completed

    A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)

    Rezpegaldesleukin, Placebo

    Alopecia Areata

    Enrollment
    94
    Start
    Apr 2024
    Primary Completion
    Nov 2025
    Completion
    Aug 2026
    NCT06340360
  • Phase 1/2
    Completed

    A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors

    NKTR-214

    Unspecified Adult Solid Tumor, Protocol Specific

    Enrollment
    28
    Start
    Dec 2015
    Primary Completion
    Oct 2018
    Completion
    Oct 2018
    NCT02869295
  • Phase 1/2
    Completed

    A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors

    Dose Escalation Doublet: Combination of NKTR-214 + nivolumab, Dose Expansion Doublet: Combination of NKTR-214 + nivolumab

    Melanoma, Renal Cell Carcinoma +5

    Enrollment
    557
    Start
    Dec 2016
    Primary Completion
    Apr 2022
    Completion
    Apr 2022
    NCT02983045
  • Phase 1/2
    Terminated

    Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors

    NKTR-214, Pembrolizumab

    Non-Small Cell Lung Cancer

    Enrollment
    162
    Start
    Jun 2017
    Primary Completion
    Jul 2022
    Completion
    Aug 2022
    NCT03138889
  • Phase 1/2
    Terminated

    REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies

    NKTR-262, bempegaldesleukin

    Melanoma, Merkel Cell Carcinoma +5

    Enrollment
    64
    Start
    Mar 2018
    Primary Completion
    May 2022
    Completion
    May 2022
    NCT03435640

1-25 of 39

Search ClinicalTrials.gov for “Nektar Therapeutics”